Narcolepsy

Narcolepsy (1) is a rare and lifelong neurological disorder that affects the brain’s ability to control the sleep–wake cycle. Narcolepsy is a complex disorder that is thought to have a genetic component, but the specific genetic causes are not yet fully understood.

People with narcolepsy experience excessive daytime sleepiness and difficulty staying awake during the day as well as disruptions in their normal sleep patterns at night.

The overall prevalence of narcolepsy is estimated to be around 0.02–0.05% of the general population.

Narcolepsy is a chronic neurologic disorder affecting the sleep-wake cycle in the brain. It is divided into two subtypes based on clinical presentation and referred to as type 1 and type 2.

  • Narcolepsy Type 1 (NT1) is caused by extensive loss of hypothalamic neurons that produce the neuropeptides orexin-A and -B (also referred to as hypocretin-1 and -2).
  • Narcolepsy Type 2 (NT2) includes most of the same symptoms, but with normal hypocretin levels and rarely cataplexy. Its cause is unknown.

Narcolepsy, first described in 1880, is characterized by excessive hypersomnolence, cataplexy, hypnagogic/hypnopompic hallucinations, sleep paralysis, automatic behaviors and sleep onset rapid-eye movement (REM) periods.

Cataplexy, defined as brief episodes of muscle atonia evoked by strong, mainly positive, emotions, is the pathognomonic symptom of NT1, while NT2 does not present with strictly defined cataplexy.

  • Up to 0%

    of patients with narcolepsy have cataplexy (NT1)

  • 25 to 0 per 100,000 people

    Estimation for prevalence for NT1

  • 20 to 0 per 100,000 people

    Estimation for prevalence for NT2

Glossary of abbreviations

  • ADHD: Attention-Deficit / Hyperactivity Disorder
  • EDS: Excessive Daytime Sleepiness
  • ESS: Epworth Sleepiness Scale
  • MSLT: Multiple Sleep Latency Test
  • NT1: Narcolepsy Type 1
  • NT2: Narcolepsy Type 2
  • PSG: Polysomnography
  • REM: Rapid Eye Movement

References

1. Mațotă AM, Bordeianu A, Severin E, Jidovu A. Exploring the Literature on Narcolepsy: Insights into the Sleep Disorder That Strikes during the Day. NeuroSci. 2023 Oct 12;4(4):263-279. doi: 10.3390/neurosci4040022. PMID: 39484177; PMCID: PMC11523731.
2. Anderson D. Narcolepsy: A clinical review. JAAPA. 2021 Jun 1;34(6):20-25. doi:10.1097/01. JAA.0000750944. 46705.36. PMID: 34031309
3. Ohayon MM, Duhoux S, Grieco J, Côté ML. Prevalence and incidence of narcolepsy symptoms in the US general population. Sleep Med X. 2023 Nov 30;6:100095. doi: 10.1016/j.sleepx.2023.100095. PMID: 38149177; PMCID: PMC10749896.
4. Scammell TE. Narcolepsy. N Engl J Med. 2015 Dec 31;373(27):2654-62. doi: 10.1056/NEJMra1500587. PMID: 26716917.
5. Franceschini C, Pizza F, Cavalli F, Plazzi G. A practical guide to the pharmacological and behavioral therapy of Narcolepsy. Neurotherapeutics. 2021 Jan;18(1):6-19. doi: 10.1007/s13311-021-01051-4. Epub 2021 Apr 22. PMID: 33886090; PMCID:
6. Szabo ST, Thorpy MJ, Mayer G, Peever JH, Kilduff TS. Neurobiological and immunogenetic aspects of narcolepsy: Implications for pharmacotherapy. Sleep Med Rev. 2019 Feb;43:23-36. doi: 10.1016/j.smrv.2018.09.006. Epub 2018 Nov 8. PMID: 30503715; PMCID: PMC6351197.
7. Golden EC, Lipford MC. Narcolepsy: Diagnosis and management. Cleve Clin J Med. 2018 Dec;85(12):959-969. doi: 10.3949/ccjm.85a.17086. PMID: 30526757.
8. Bassetti CLA, Adamantidis A, Burdakov D, Han F, Gay S, Kallweit U, Khatami R, Koning F, Kornum BR, Lammers GJ, Liblau RS, Luppi PH, Mayer G, Pollmächer T, Sakurai T, Sallusto F, Scammell TE, Tafti M, Dauvilliers Y. Narcolepsy – clinical spectrum, aetiopathophysiology, diagnosis and treatment. Nat Rev Neurol. 2019 Sep;15(9):519-539. doi: 10.1038/s41582-019-0226-9. Epub 2019 Jul 19. PMID: 31324898.

GLO – NEURO – 05/2026-02

Last updated: May 2026